BioCentury
ARTICLE | Company News

Abbott, Boston Scientific deal

May 1, 2006 7:00 AM UTC

ABT acquired the vascular business of BSX's Guidant Corp. unit for $4.1 billion in cash. ABT also will purchase $1.4 billion of BSX stock, which is less than a 5% stake in the company. BSX is eligible for a $250 million milestone payment upon FDA approval of Guidant's Xience V everolimus-eluting stent and an additional $250 million upon Japanese approval. ...